TATVA Tatva Chintan Pharma Chem Q1 FY27 results (Apr–Jun 2026) and concall
Tatva Chintan Pharma Chem Limited reported robust Q1 FY27 results with significant YoY growth in revenue and EBITDA, driven by strong performance in PTC, PASC, and SDA segments. A key highlight was the successful qualification of its first commercial-scale semiconductor product and the approval of a new INR 200 crore greenfield facility. While the Electrolyte Salts segment faced headwinds from raw material shortages, management expressed confidence in maintaining a 20-25% compounded annual growth rate over the next 3-4 years and an EBITDA margin of 20-22%.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 42.7%, net profit up 128.6% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 86 | 108 | 117 | 124 | 131 +52% | 134 +24% | 167 +43% |
| EBITDA | 7 | 9 | 17 | 22 | 25 +257% | 28 +211% | 32 +88% |
| Net profit | 0 | 1 | 7 | 10 | 15 | 10 +900% | 16 +129% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
